Source: International Congress 2017 – Bronchiectasis and NTM infections: epidemiology, phenotyping and therapeutic strategies
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
K. Yagi (Tokyo, Japan). The efficacy, safety and feasibility of inhaled amikacin for the treatment of refractory non-tuberculous mycobacterial lung diseases. 4073

Member's Comments

No comment yet.

Related content which might interest you: The tolerability of linezolid in the treatment of nontuberculous mycobacterial disease Source: Eur Respir J 2015; 45: 1177-1179 Year: 2015 Evaluation of the efficacy and safety of moxifloxacin in the treatment of drug-resistant pulmonary tuberculosis; a clinical trial Source: Annual Congress 2008 - Multidrug-resistant and the emerging threat of extensively drug-resistant tuberculosis Year: 2008 Evaluation of the efficacy and safety of levofloxacin in the treatment of resistant pulmonary tuberculosis; a clinical trial Source: Eur Respir J 2002; 20: Suppl. 38, 546s Year: 2002 Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia Source: Eur Respir J 2003; 21: 135-143 Year: 2003 The efficacy of treatment of patients with drug resistant tuberculosis Source: Eur Respir J 2007; 30: Suppl. 51, 661s Year: 2007 Clinical efficacy and safety of fluoroquinolone containing regimens in patients with Mycobacterium avium complex pulmonary disease Source: Eur Respir J, 55 (4) 1901240; 10.1183/13993003.01240-2019 Year: 2020 A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis Source: Eur Respir J 2009; 33: 387-393 Year: 2009 Clinical efficacy and safety of clarithromycin in the treatment of multi-drug resistant tuberculosis Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance Year: 2009 Efficacy and safety of levamisole as an immunomodulator in the treatment of drug resistant tuberculosis Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II Year: 2019 A study on the clinical efficacy of a combination regimen with azithromycin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 722s Year: 2004 The efficacy of treatment with surfactant-BL (S-BL) in patients with destructive pulmonary tuberculosis Source: Annual Congress 2007 - Research perspectives: diagnosis and treatment of tuberculosis Year: 2007 Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis Source: Eur Respir J 2012; 40: 1430-1442 Year: 2012 Treatment of severe Mycobacterium avium complex pulmonary disease with a adjunctive amikacin and clofazimine versus standard regimen alone, a retrospective study Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection I Year: 2019 Clinical efficacy and safety of micafungin in patients with pulmonary aspergillosis Source: Eur Respir J 2006; 28: Suppl. 50, 788s Year: 2006 Efficacy and safety of chemotherapy regimens containing fluoroquinolones in pediatric TB Source: Virtual Congress 2021 – Epidemiology and burden of tuberculosis and other lung diseases Year: 2021 Side-effect in the treatment of pulmonary tuberculosis by first-line drugs Source: Annual Congress 2009 - Tuberculosis: metabolism and comorbidities Year: 2009 Efficacy and safety of various antimicrobial regimens in the treatment of acute exacerbations of chronic bronchitis Source: Annual Congress 2007 - Infectious lung and pleural diseases Year: 2007 Efficacy and tolerability of voriconazole in the treatment of pulmonary aspergillosis Source: Eur Respir J 2007; 30: Suppl. 51, 301s Year: 2007 A study of role of rifabutin as an adjuvant in management of cases with multi-drug resistant pulmonary tuberculosis Source: Annual Congress 2007 - Medical and surgical treatment of susceptible and resistant tuberculosis Year: 2007